Paper Details

  1. Home
  2. Paper Details

GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo.

Author: ChanShingpan, DingKe, GuoJing, HeRui, JiangKaili, RenXiaomei, SongXiaojuan, TangXia, TuZhengchao, WangYuting, ZhangZhang

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated a third-generation ABL inhibitor, GZD824, as a potential treatment for certain types of cancer resistant to other FGFR inhibitors. The study found that GZD824 effectively overcomes resistance caused by mutations in the FGFR1 gene, including the V561M mutation, both in laboratory studies and in animal models. These findings suggest that GZD824 could be a promising treatment option for patients with FGFR1-related cancers that have become resistant to other therapies.
Paper Details　
Original Abstract of the Article :
Abnormallyactivated FGFR1 has been validated as a therapeutic target for differentcancers. Although a variety of FGFR inhibitors have shown benefit in manyclinical patients with FGFR1 aberration, FGFR1 mutant resistance such as V561Mmutation, has been reported. To date however, no FGFR inhibitors ha...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290231/

データ提供：米国国立医学図書館（NLM）

A Novel ABL Inhibitor, GZD824, Shows Promise in Overcoming FGFR1 Mutant Resistance

The world of cancer treatment is a vast desert, full of challenges and obstacles. One such challenge is the development of resistance to targeted therapies. In the field of [oncology], the discovery of new drugs that can overcome this resistance is a crucial goal. This particular study delves into the fascinating world of FGFR1 mutations, which can lead to resistance to FGFR inhibitors. Researchers have discovered a glimmer of hope in the form of GZD824, a third-generation ABL inhibitor, which shows promise in overcoming this resistance. This study, like a trusty camel traversing the desert, sheds light on a potential solution to this problem.

GZD824: A Potential New Weapon in the Fight Against FGFR1 Mutant Resistance

The study found that GZD824 effectively inhibits the growth of Ba/F3-FGFR1-V561F/M mutant xenograft tumors in vivo. This finding is particularly exciting as it demonstrates the potential of GZD824 in treating patients with FGFR1 mutant resistance. The researchers have shown that GZD824 can effectively overcome resistance in Ba/F3 stable cells and inhibit tumor growth in vivo. This is like finding an oasis in the desert – a refreshing and promising discovery in the search for effective cancer treatments.

GZD824: A Potential New Weapon in the Fight Against FGFR1 Mutant Resistance

While GZD824 shows great potential in treating FGFR1 mutant resistance, it is still in its early stages of development. Further research is needed to confirm its effectiveness in humans. However, this discovery holds immense promise for future treatment options for patients with FGFR1 abnormalities. This research is like a beacon of hope in the desert, illuminating a path toward a brighter future for patients battling cancer.

Dr.Camel's Conclusion

This study highlights the importance of research in developing novel therapies to overcome drug resistance in cancer. GZD824 has emerged as a potential new weapon in the fight against FGFR1 mutant resistance, bringing hope to patients facing this challenge. Just like a camel navigates the treacherous desert, this research is paving the way for a more promising future for cancer treatment.

Date :
  1. Date Completed 2021-12-31
  2. Date Revised 2022-04-01
Further Info :

Pubmed ID

34114373

DOI: Digital Object Identifier

PMC8290231

Related Literature

Article Analysis
・Effects of futibatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.